Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited treatment options upon progression. Genomic profiling European (Arcagen cohort) and French (AURAGEN cohort) initiatives aim to guide treatments for rare cancers. This study presents the initial findings from these efforts. Molecular analysis (n = 56, 55.4% females, mean 55.9 years) showed a high success rate to identify clinically relevant mutations; the majority of patients harbored BAP1 , NF2 , and CDKN2A/B mutations. Notably, one patient harbored an ALK :: STRN fusion, potentially leading to a specific targeted treatment. The AURAGEN cohort identified more gene mutations overall, though few were directly actionable, but provided new alterations to consider for trials, such as EWSR1 :: YY1 . Both cohorts identified similar proportions of therapeutic targets. Comprehensive genomic profiling provides valuable insights into treatment options. While different methods identified similar therapeutic targets, initiatives like AURAGEN offer additional genetic data for therapeutic decisions and drive future therapeutic developments.
